InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: cheynew post# 210793

Friday, 03/13/2015 11:01:03 AM

Friday, March 13, 2015 11:01:03 AM

Post# of 346050
MLV kept this at $3.50 ? Hmmmm... seems like they are keeping it low for other preferred reasons.

Does not make sense at all. The times when MLV says $3.50 that was placed with some risk and no peek into the future. Now, many months later Peregrine continues to reduce risk and that should be reflected in the MLV price target.

I'm not going to predict what they should have stated, but its obvious that when a company such as Peregrine just expressed their combination potential of PS Targeting and MLV places $3.50 on the target is completely off and under the mark.


"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News